Advances in Urology

Clinical Study

Comparative Evaluation of the Safety and Efficacy of Long-Term Use of Imidafenacin and Solifenacin in Patients with Overactive Bladder: A Prospective, Open, Randomized, Parallel-Group Trial (the LIST Study)

Table 2

Baseline characteristics of subjects for long-term analysis set.
DemographicsImidafenacinSolifenacinP-value
Subjects1114
Age (years)(Mean ± SD) 6 9 . 9 ± 6 . 7 7 1 . 4 ± 6 . 0 0 . 5 5 6 0 a
 <60, n (%)0 (0%)0 (0%)
 ≥60, n (%)4 (36.4%)4 (28.6%)
 ≥70, n (%)7 (63.6%)10 (71.4%)
Gender
 Male, n (%)7 (63.6%)10 (71.4%) 1 . 0 0 0 0 b
 Female, n (%)4 (36.4%)4 (28.6%)
OABSS (total score)(Mean ± SD) 9 . 0 ± 1 . 3 8 . 9 ± 2 . 6 0 . 8 4 5 3 c
Siverity of OABSS
 Mild, n (%)0 (0%)3 (21.4%) 0 . 3 6 7 1 c
 Moderate, n (%)11 (100%)10 (71.4%)
 Severe, n (%)0 (0%)1 (7.1%)
Postvoid residual volume (mL)(Mean ± SD) 1 5 . 1 ± 1 4 . 7 1 3 . 4 ± 1 1 . 0 0 . 7 4 8 7 a
Each urination volume (mL)(Mean ± SD) 1 2 5 . 3 ± 8 5 . 0 2 0 3 . 8 ± 1 7 9 . 8 0 . 1 6 5 4 a
Urination time (second)(Mean ± SD) 2 9 . 1 ± 2 3 . 0 2 6 . 1 ± 1 0 . 7 0 . 6 9 3 9 a
Qmax (mL/s)(Mean ± SD) 1 1 . 2 ± 8 . 8 1 4 . 8 ± 1 1 . 8 0 . 4 1 2 0 a
In male
 Prostate volume (mL)(Mean ± SD) 2 1 . 0 ± 9 . 1 2 7 . 8 ± 8 . 2 0 . 1 3 0 2 a
 Use of α1 blocker, n (%)6 (85.7%)9 (90.0%) 1 . 0 0 0 0 b
Severity of OAB was defined as total OABSS score ≤5: mild; 6 to ≤11: moderate; ≥12: severe
a: Unpaired t-test, b: Fisher’s exact test, c: Mann-Whitney U test, two-sided. SD: standard deviation.